Introduction: Why Fusion Matters Biologics are entering a new era—one not defined solely by monoclonal antibodies but by engineered fusion constructs. The antibody was the great engine of the last two decades, dominating pipelines across oncology, autoimmunity, and rare disease. But today, as pipelines diversify, the limitations of conventional antibodies are increasingly clear. Fusion proteins—Fc-fusions, […]